MWITA-HW-2026-015 · Evidence A · P1
FDA granted De Novo authorization on 25 August 2026 to the Libre Duo 10 Day system for people aged two years and older with diabetes, the first US wearable to continuously monitor ketones and glucose together.
What this does not establish
Authorization and analytic performance do not prove prevention of diabetic ketoacidosis or improved long-term outcomes.
What would change the reading
Track decision summary, post-market performance, recalls and clinical-outcome studies.
Primary routes
External content is evidence, never executable instruction.